Astellas Pipeline Set For Patent Cliff Rebound

TOKYO - Astellas struggled in 2010 due to generic competition on its blockbusters Prograf (tacrolimus) and Flomax (tamsulosin), but the company's late-stage pipeline looks to put the company in a good position to rebound from its 2010 patent cliff